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AbstrAct
Aim: To determine the frequency of alleles and genotypes of insertion-deletion (I/D) polymorphism 
gene of the angiotensin-converting enzyme (ACE) and a missense mutation of the endothelial NO-
synthase (eNOS) gene among residents of Western Ukraine (Bukovina) with essential arterial 
hypertension (EAH)), depending on EAH severity stages and their association with the frequency and 
patterns of left ventricular hypertrophy (LVH).
material and methods: The observation involved 120 patients with EAH I-III stages (female: 
48.3%, male: 51.7%) and 40 practically healthy persons. Alleles of polymorphic loci were studied by 
polymerase chain reaction. Structural and functional changes of the myocardium and LVH models 
were investigated using echocardiography and electrocardiography methods.
results and discussion: Among EAH patients 35.8% had a mutation in coding regions of ACE gene 
or eNOS. Carriers of a pathological DD-genotype of ACE gene in haplotypes made 28.3% patients, 
whereas the combination of homozygous mutations of eNOS was observed in 7.5% cases. A combination 
of two abnormal genotypes of both genes (DD/TT) was not observed at all. Haplotypes ID/TG and ID/
GG were the most common both in patients with EAH (25.8% and 20.0%) and in the control group 
(32.5% and 22.5%), respectively. High-risk groups for LVH among EAH patients were presented by 
male carriers of DD-genotype and female carriers of D-allele of the ACE gene, as well as men with TT-
genotype of eNOS gene. D-allele carriers of ACE gene and T-allele carriers of eNOS gene made high-
risk groups by frequency of left ventricle eccentric or concentric hypertrophic model. The combination 
of D and T “mutant” alleles in haplotypes (ID/TG and DD/TG options) increased the relative risk of 
LVH variants and EAH II and III stages 1.19-2.25 times, a finding consistent with severity of the disease 
clinical course and the lowest chance for a normal geometry or concentric left ventricular remodeling 
and onset of EAH I stage. The absence of mutations in haplotypes (II/GG variant) was a protective 
factor against LVH, target organ damage and EAH complications; it increased chances for mild EAH I 
stage 1.44 times and favourable patterns of left ventricular geometric structure 2.53 times.
Conclusion: The ID/TG and DD/TG combinations of genotypes of ACE (I/D) and eNOS (893T>G) 
genes are the additional independent predictors of target-organ damage, in particular for appearance 
of LVH, and the severity of EAH.
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medicine today. The basis of the modern strategy 
for medical management of specified patients is to 
achieve adequate control of blood pressure (BP), 
limit the formation and progression of target organ 
damage and prevent the occurrence of comorbid 
conditions and metabolic atherothrombotic events 
[Fagard R. et al., 2009; Sydorchuk L., Amosova K., 
2011]. Among the CVDs one of the most common 
is arterial hypertension (AH) that makes from 
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IntroductIon
The use of molecular genetics methods to iden-
tify and assess genetic risk factors for early detec-
tion of cardiovascular disease (CVD) before the 
onset of clinical symptoms is an actual problem of 
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5.1% in Asia to 70.7% in Western Europe [Kear-
ney P. et al., 2005; Jaddou H. et al., 2011]; from 
25.2% to 75.0% of patients are aware of the pres-
ence of hypertension, while controlled BP is re-
corded only in 5.4-58.0% of cases. In Ukraine, hy-
pertension is diagnosed in 32.2% of adults; 80.8% 
of patients in the urban population and 67.8% in 
rural area are aware of it, 48.4% and 38.3% are 
treated, and the effectiveness of treatment is only 
18.7% and 8.1%, respectively [Working group on 
Hypertension, 2012]. Left ventricular hypertrophy 
(LVH) develops in 60% patients with AH and thus 
determines the risk magnitude of cardiovascular 
events (CVE) [Mancia G. et al., 2009; ESC Guide-
lines, 2010]. However, LVH is not only a result of 
the implementation of the hemodynamic compo-
nent of the renin-angiotensin-aldosterone (RAAS), 
NO and the sympathetic-adrenal system, 60.0% of 
LVH appears regardless of BP [Deschepper C. et 
al., 2002; Fraser R., 2003; Sydorchuk L., 2010]. 
Angiotensin-2 (AT2) plays an important role in the 
manifestation of the clinical phenotype of CVD, 
including the essential arterial hypertension (EAH) 
[Tikellis C., Thomas M., 2012]. Some authors have 
found that AT2 promotes expression of “immedi-
ate-early” fetal genes such as jun B, erg-1, c-myc, 
c-fos, c-jun, which are responsible for the intensity 
of myocardial intracellular protein synthesis, sig-
nal transduction and activate fetal type of metabo-
lism [Dias-Peixoto M. et al., 2012]. 
Increased expression of genes of the heavy 
β-myosin chain, α-actin, atrial natriuretic peptide 
is accompanied by an increase in fetal isoforms of 
contractile proteins and the formation of LVH, re-
spectively [Verdecchia P. et al., 2012] with a sub-
sequent decrease of the relaxation first, and then 
the pumping function of the heart [Fournier D. et 
al., 2012]. The participation of the majority of mo-
lecular and cellular mechanisms of RAAS NO-sys-
tem in the progression of CVD, EAH and LVH re-
alization were mainly studied in experimental 
models in vitro, including the morphological level 
[Sydorchuk I. et al., 2000]. Part of the pathogenetic 
mechanisms is not yet fully established, the role of 
key genes mutations are not fully understood, 
some data are contradictory and significantly dif-
ferent in separate populations, ethnic groups and 
races [Conen D. et al., 2009; Paynter N. et al., 
2009; Rai Н. et al., 2012]. Separate clinical and 
prognostic values of many genetic factors are gen-
erally unknown and require further study.
The aim of the present study was to evaluate the 
frequency of alleles and genotypes of insertion-de-
letion (I/D) polymorphism of the angiotensin-con-
verting enzyme (ACE) (dbSNP id: rs4646994) and a 
missense mutation (894T<G polymorphism) of the 
endothelial NO-synthase (eNOS) gene (dbSNP id: 
rs1799983 ) among residents of Western Ukraine 
(Bukovina), patients with EAH depending on the 
severity of EAH stages and their association with 
the frequency and patterns of LVH.
MaterIaL and MethodS
In prospective study we included 150 patients 
with EAH I-III stages of severity with average office 
BP greater than 140/90 mm Hg measured according 
to the requirements of ESC/ESH(2009) [Mancia G. 
et al., 2009] and disease duration from 2 to 28 years 
(mean: 15.73±8.02 years). All the patients were 
treated in the Regional Clinical Cardiology Dispen-
sary and the Municipal Ambulatory Hospital No.1 in 
Chernivtsi city (Ukraine). The genetic research was 
performed in the Laboratory of Medical Biology and 
Genetics Department at Bukovina State Medical 
University (BSMU). The research list and patients’ 
Prior Informed Consent Form were approved by the 
Biomedical Ethics Commission of BSMU, Ministry 
of Health of Ukraine.
After screening (matching inclusion/exclusion 
criteria) 120 EAH patients were selected for fur-
ther examination. Group distribution by target-or-
gan damage and complications appearance was 
performed according to WHO classifications, 
guidelines of national and European Societies of 
Cardiology and Hypertension [Mancia G. et al., 
2009; ESC Guidelines, 2010]. Among the selected 
cohort 12.5% (n=15)  of patients were with EAH I 
stage, 60.0% (n=72) ‒ with EAH II stage; 27.5% 
(n=33) ‒ with EAH III stage. Female patients made 
48.3% (n=58) and male ‒51.7% (n-62); mean age 
made 52.91±9.24 years. The control group in-
volved 40 practically healthy individuals of appro-
priate age and gender (p>0.05).
Exclusion criteria were as follows: symptom-
atic hypertension, sub- and decompensated liver 
diseases (AST, ALT levels three times above the 
normal upper limit), decompensated renal diseases 
(serum creatinine 200 μmol/L and above), chronic 
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heart failure (CHF) higher than II class (NYHA), 
ejection fraction (EF) less than 45%, acute coro-
nary syndrome 3 months prior to survey, acute 
heart failure, acute stroke prescription 3 months 
prior, diabetes mellitus type 1 (DM1), sub- and de-
compensated type 2 diabetes (DM2), mental disor-
ders. Subjects taking corticosteroids, oral contra-
ceptives, as well as those with exacerbation of 
chronic inflammatory processes or background 
endocrine and acute inflammatory processes, 
wherever located, women in pregnancy and lacta-
tion period were also excluded from the survey.
Office systolic and diastolic BP, heart rate (HR) 
were measured according to European guidelines 
ESC/ESH (2009) [Mancia G. et al., 2009]. The 24-
hour blood pressure monitoring (ABPM) was per-
formed on “ABPE-02” (“SOLVAIG”, Ukraine-
France) and “ABPM” (“Meditech”, Hungary) ac-
cording to the standard protocol (40-55 measure-
ments/day). Data analysis was performed with the 
software of mentioned devices.
Genomic DNA was extracted from peripheral 
blood leukocytes using the test system “DNA-
sorb-B” (Russia), with primers specific to the al-
leles’ genes [Entrez Gene, 2011]. Amplified poly-
morphic locus was detected by polymerase chain 
reaction on “Amply-4L” amplificator according to 
the manufacturer’s protocol. Alleles’ discrimina-
tion of eNOS gene was performed by restriction 
endonuclease BanII (Eco241) (“Fermentas”, 
USA). Amplified DNA fragments were separated 
by gel electrophoresis, stained with xylene zianol, 
visualized by transluminator  in the presence of 
molecular mass ladder/marker (100-1000 bp).
The LVH was estimated using M- and B-modes 
of echocardiography (Echo-CG) on automated diag-
nostic complex “SonoAce8000 SE” (“Medison”, 
Korea), standard linear indicators of structural and 
functional state of the left ventricle (LV) were ana-
lyzed, including the LV geometry. The LV mass 
(LVM) was evaluated according to the Penn Con-
vention, LVM index (LVMI) was calculated by the 
ratio of LVM to body surface area (g/m2). The crite-
ria of LVH, according to the European Guidelines 
(ESC/ESH, 2009) were as follows: LVMI in men 
≥125 g/m2, in women ≥110 g/m2. According to 
LVMI and LV relative wall thickness (RWT) we 
identified the following geometric models of LV 
(ESC/ESH, 2009): LV normal geometry (LV NG), 
LV concentric remodeling (LV CR), eccentric LVH 
(LV EH), concentric LVH (LV CH). In addition, pa-
tients’ examination list included electrocardiogram 
in 12 standard leads, ultrasound of kidneys and ab-
dominal organs, clinical and biochemical analysis, 
consulting by ophthalmologist and neurologist. 
Statistical processing was performed with MS ® 
Excel ® 2003 ™, Primer of Biostatistics ® 6.05 and 
Statistica ® 7.0 (StatSoft Inc., USA) programs soft-
ware. Differences in continuous variables between 
cases and controls were analyzed using the unpaired 
Student’s t-test (distribution by Kolmogorov-
Smirnov and W-Shapiro-Wilk test was near to nor-
mal) or U-test Wilcoxon-Mann-Whitney; analysis 
of qualitative data (categorical variables) was done 
using the chi-square test (χ2), including deviation 
from the Hardy-Weinberg equilibrium, comparison 
of allele frequencies with 1 degree of freedom (df), 
haplotypes and genotypes between the groups and 
the control with 2 df. The associations between al-
leles or genotypes, and EAH and LVH severity were 
analyzed using odds ratio (OR) with 95% confi-
dence intervals (CI). The differences were consid-
ered significant at p<0.05.
reSuLtS
Among EAH patients mutation in intron 16 of 
ACE gene was observed in 28.3%, that was 1.4 
times more frequent than in the control group (χ2= 4.34; 
p=0.037). In healthy subjects the “wild” I allele fre-
quency of ACE gene exceeded that in hypertensive 
patients by 6.7% (p<0.001), respectively (Table 1). 
Carriers of D allele insignificantly dominated (52.5 
versus 47.5% I allele, χ2<1.0; p>0.05, respectively) 
in quantitative and relative aspects. 
The distribution obtained in observed groups re-
flected the general picture in the studied population; 
this latter was confirmed by the calculation of in-
breeding coefficient (F) with unreliable heterozy-
gote excess (F =-0.04-0.10; p>0.05), spread to the 
whole sample (F =-0.05; p<0.05), and indicated a 
normal population distribution corresponding to the 
expected Hardy-Weinberg equilibrium (Table 2).
“Wild” G allele of eNOS gene was observed in 
214 (66.9%) of the 320 cases of selected alleles, 
where in a 7-chromosome 7 exon q35-36 of eNOS 
gene no missense mutation occurred with struc-
tural nucleotide substitution of thymine for gua-
nine (T®G) and subsequent synthesis of modified 
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protein G [Glu]®A[Asp]. Unfavourable “minor” 
T-894 (Asp) variant was recorded 2 times less fre-
quent than the G allele: 106 cases (33.1%) (χ2=7.15; 
p=0.011). Similar frequency distribution was ob-
served in both experimental and control groups 
(Table 1), where “wild” G allele significantly pre-
vailed over mutant allele: 65.8% versus 34.2% in 
the experimental group (χ2=6.37; p=0.012) and 
70.0% versus 30.0% (χ2=7.41; p=0.008) in the 
control, respectively. However, the distribution of 
“minor” and “mutant” alleles of EAH patients and 
healthy control groups were not significantly dif-
ferent (χ2=<1.0; p>0.05). Allelic distribution 
among the observed cohort was within the ex-
pected Hardy-Weinberg equilibrium (Table 3) with 
the insignificant tendency to heterozygosity in-
crease in all observed groups (F=-0.18-0.43) and 
overall (F=-0.24), with no statistically significant 
difference (p>0.05).
In patients with EAH II and III stages the “mu-
tant” D allele was found 4.5 and 7.3 times more fre-
quent, respectively, than the II-genotype (81.9-87.9% 
against 12.1-18.1% (χ2=7.35-14.28; p≤0.007-0.001). 
Among patients with EAH I stage the favorable I al-
lele was recorded 6.5 times more frequent than the 
DD-genotype (χ2=5.53; p=0.048). In general, DD-
genotype was by 8.3% more common in patients with 
EAH (Table 1) than in healthy subjects (χ2=5.35, 
OR=3.04, 95%CI=1.16-3.9; p=0.021), with no sig-
nificant differences in the frequency of ID-genotype. 
tAble 1.
The allele frequencies and genotype of ACE (I/D), eNOS (894T>G) genes polymorphism 
in association with arterial hypertension
Groups
Control group, 
n=40
Hypertension, 
n=120 χ2 OR (95% CI) р
% n % n
Alleles
АСЕ gene
I 42 52.5 110 45.8 16.02 3.02 (1.77-5.13) <0.001
D 38 47.5 130 54.2 16.36 3.04 (1.79-5.17) <0.001
eNOS gene
T 24 30.0 82 34.2 0.30 1.21 (0.70-2.09) 0.58
G 56 70.0 158 65.8 0.47 0.82 (0.48-1.43) 0.49
Genotypes
АСЕ gene
II 10 25.0 24 20.0 4.36 2.98 (1.17-7.71) 0.037
ID 22 55.0 62 51.7 0.79 0.66 (0.27-1.65) 0.51
DD 8 20.0 34 28.3 5.35 3.04 (1.16-3.93) 0.021
eNOS gene
GG 16 40.0 47 39.2 0.01 0.97 (0.46-2.01) 0.92
TG 24 60.0 64 53.3 12.52 3.02 (1.66-5.48) 0.004
TT 0 0 9 7.5 – – –
notes: OR=odds ratio; CI=confidence interval.
tAble 2.
Analysis of heterozygosity and allelic state of the ACE I/D gene polymorphism 
Groups
Alleles
Р
І
Рd НО НЕ f χ
2 pІ d
n % n %
EAH patients 110  45.8 130 54.2 0.45 0.54 0.52 0.49 -0.04 <1.0 >0.05
Control 42 52.5 38 47.5 0.53 0.47 0.55 0.50 -0.10 <1.0 >0.05
Total 152 47.5 168 52.5 0.48 0.52 0.52 0.50 -0.05 <1.0 >0.05
notes: Р
І
 – relative I allele frequency; РD – relative D allele frequency. НO –heterozygosity observed; НЕ –het-
erozygosity expected; F – inbreeding coefficient (deviation of genotypic frequencies from panmictic fre-
quencies in terms of heterozygous deficiency or excess); χ2 (p) – criterion of the “zero” hypothesis validity 
between observed and expected heterozygosity.
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Among II-genotype carriers the number of EAH II 
patients were significantly, 1.85 times, greater than 
those with EAH I stage (χ2=15.38; p<0.001). The total 
frequency of II-genotype by 5.0% (p=0.037) prevailed 
in control group versus the experimental one. 
Homozygous mutation in the eNOS gene (TT 
genotype) was found only in patients with severe 
target-organ damage and complications (EAH II 
and III) with the same relative frequency (55.5% 
and 44.5%; p>0.05). EAH III stage was associated 
with the dominance of “mutant” TT genotype 1.5-
2.1 times compared to the G allele (χ2=6.06-11.13; 
p≤0.014-0.001). Among the favorable GG-geno-
type carriers of eNOS gene EAH I stage patients 
dominated 1.54-1.98 times (60.0% versus 38.9% 
and 30.3% of EAH II and III patients, respectively 
(χ2=4.36-22.3; p≤0.037-0.001). EAH I and II 
stages were associated with G allele higher fre-
quency (1.27-1.4 times) as compared to TT geno-
type (χ2= 11.12-17.26; p<0.001). Overall, in pa-
tients with EAH the TG-genotype of eNOS gene 
was detected 6.7% more frequent than in the con-
trol group (χ2=12.52, OR=3.02, 95% CI=1.66-
5.48; p=0.004), with no significant differences in 
the frequency of GG-genotype; TT genotype was 
absent among control subjects (Table 1).
According to Echo-CG the size of the left 
atrium (LA), end-diastolic and end-systolic sizes 
and volumes (EDS, ESS, EDV, ESV), EF between 
genotypes of ACE gene were not significantly dif-
ferent, but the LV posterior wall thickness in dias-
tole (PWTd) and interventricular septum in dias-
tole (IVSd) substantially prevailed in DD-geno-
type carriers by 20.4% and 21.7% (p<0.05) than in 
II-genotype carriers, and by 11.7% and 17.3% 
(p<0.05) than in I/D-genotype carriers, respec-
tively. LVM and LVMI in men was also greater in 
DD-genotype carriers of ACE gene (p≤0.05-
0.009), but the LVMI in women was associated 
with D-allele and prevailed the index in homozy-
gous I-allele carriers by 32.5% (p<0.03) and 20.3% 
(p<0.05), respectively. The RWT did not differ be-
tween genotypes of ACE gene in hypertensive sub-
jects, but was significantly higher in EAH patients 
with DD-genotype, than in controls. The T894G 
polymorphism analysis of eNOS gene showed that 
the sizes of the LA in T-allele carriers exceeded 
those in patients with GG-genotype by 19.7% 
(p<0.05) and 21.5% (p<0.03), with no difference 
after EF, EDS, ESS, EDV, ESV and PWTd, IVSd 
between genotypes in EAH patients. LVM was not 
significantly higher in T-allele carriers, with more 
reliable difference of LVMI also in T-allele carri-
ers, but only in men, by 18.0% (p<0.04) and 16.9% 
(p=0.05), respectively.
The haplotypes distribution of examined genes is 
shown as Table 4. Mutations in two genes were not 
found in 8.1% (n=13) patients: 5.6% (n=9) – in the 
experimental group, 2.5% (n=4) – in control. Patho-
logical DD variant of ACE gene was recorded al-
most in one fourth of surveyed (26.3%; n=42): 
21.3% (n=34) – in the experimental group, 5.0% 
(n=8) – in control (χ2=4.34; p=0.037). The eNOS 
gene mutation was observed 4.7 times less frequent 
than ACE gene mutation: 5.6% (n=9) cases among 
patients and none in the control group. Nearly one 
third patients with EAH (35.8%) were the homozy-
gous “minor” D allele carriers of ACE gene or the T 
allele of eNOS gene. The combination of two ab-
normal genotypes of both genes (DD/TT) was not 
tAble 3.
Analysis of heterozygosity and allelic state of the eNOS 894G>T gene polymorphism 
Groups
Alleles
РG Рt НО НЕ f χ
2 РG t
n % n %
EAH patients 158 65.8 82  34.2 0.66 0.34 0.53 0.45 -0.18 2.46 >0.05
Control 56 70.0 24  30.0 0.70 0.30 0.60 0.42 -0.43 2.28 >0.05
Total 214 66.9 106  33.1 0.67 0.33 0.55 0.44 -0.24 2.29 >0.05
Notes: РG – relative G frequency; РT – relative T allele frequency. НO –heterozygosity observed; НЕ – het-
ero-zygosity expected; F – inbreeding coefficient (deviation of genotypic frequencies from panmic-
tic frequencies in terms of heterozygous deficiency or excess); χ2 (p) – criterion of the “zero” hypoth-
esis validity between observed and expected heterozygosity.
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observed (Table 4). Heterozygous presence of both 
genes in the haplotypes or in combination with fa-
vourable homozygous variant (II/TG, ID/TG, ID/
GG) was revealed in the overwhelming majority, 
viz., 60.0% (n=96) of surveyed subjects: 42.5% 
(n=68) patients in the experimental group, 17.5% 
(n=28) – in the control (χ2=13.91; p<0.001). The 
most common combinations were ID/TG and ID/
GG haplotypes (n=77), both among the EAH pa-
tients (25.8% and 20.0%) and in control group 
(32.5% and 22.5%), appropriately (χ2=6.07; p=0.014 
and χ2=4.24; p=0.039) (Table 4).
The analysis of geometric models of the LV dis-
tribution, depending on the haplotypes of the ana-
tAble 4.
Distribution of haplotypes of ACE and eNOS genes in observed population 
Combination of genotypes of 
ACE and eNOS genes, n (%)
Groups
χ2 p OR  (95% CI)EAH patients Control
n % n %
ІІ/TT, n=2 (%) 2 1.7 0 – –
II/TG, n=19 (%) 13 10.8 6 15.0 2.05 0.152 0.34  (0.09-1.17)
II/GG, n=13 (%) 9 7.5 4 10.0 1.05 0.316 0.36  (0.08-1.39)
ID/TT, n=7 (%) 7 5.8 0 0 – –
ID/TG, n=44 (%) 31 25.8 13 32.5 6.07 0.014 0.39  (0.14-0.76)
ID/GG, n=33 (%) 24 20.0 9 22.5 4.24 0.039 0.53  (0.12-0.86)
DD/TT, n=0 (%) 0 0 0 0 – –
DD/TG, n=25 (%) 20 16.7 5 12.5 2.40 0.122 0.32  (0.10-1.10)
DD/GG, n=17(%) 14 11.7 3 7.5 1.26 0.262 0.32  (0.07-1.39)
notes: OR=odds ratio; CI=confidence interval.
tAble 5.
Geometric model of the left ventricle in patients with hypertension, 
depending on the ACE (I/D) and eNOS (894T>G) genes haplotypes
Geometric model of the left 
ventricle, n (%)
Genotypes combinations of ACe (i/d) and enos (t894G) genes
n % n % n %
ІІ/TT, n=2 (%) ii/tG, n=13 (%) ii/GG, n=9 (%)
LV NG. n=3 (2.5) 0 0 0 0 3 33.3
LV CR. n=7 (5.8) 0 0 3 23.1 4 44.4
LV EH. n=7 (5.8) 1 50.0 5 38.5 1 11.1
LV CH. n=7 (5.8) 1 50.0 5 38.5 1 11.1
id/tt, n=7 (%) id/tG, n=31 (%) id/GG, n=24 (%)
LV NG. n=5 (4.2) 0 0 0 0 5 20.8
LV CR. n=5 (4.2) 1 14.3 2 6.5 2 8.3
LV EH. n=19 (15.8) 2 28.6 13 41.9 4 16.7
LV CH. n=33 (27.5) 4 57.1 16 51.6 13 54.2
dd/tt, n=0 (%) dd/tG, n=20 (%) dd/GG, n=14(%)
LV NG. n=2 (1.7) – – 1 5.0 1 7.1
LV CR. n=3 (2.5) – – 1 5.0 2 14.3
LV EH. n=12 (10.0) – – 7 35.0 5 35.7
LV CH. n=17 (14.2) – – 11 55.0 6 42.9
notes: LV NG – normal geometry of left ventricle; LV CR – concentric remodelling of left ventricle; LV EH 
– eccentric left ventricle hypertrophy; LV CH – concentric left ventricle hypertrophy. n (%) – number 
(%) of observations.
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lyzed genes is presented as Table 5. In II/GG-hap-
lotype carriers NG and CR LV were more common 
than in patients with II/TG (χ2=12.84; p<0.001), 
ID/TT (χ2=7.65; p=0.006) and ID/GG haplotypes 
(χ2=6.23; p=0.013). Hypertrophic models (EG and 
CG LV) were significantly more frequent in pa-
tients with ID/TG-haplotype than in ID/GG-haplo-
type carriers (χ2=6.70; p=0.01) and in patients with 
ID/TT-haplotype than in II/TT patients (χ2=4.37; 
p=0.037) with the borderline advantage for those 
with II/TG-haplotype (χ2=3.76; p=0.052).
Potential genetic risk factors for complications 
or severe EAH course in six haplotypes combina-
tions are shown in Table 6. The presence of ID/TG 
and DD/TG haplotypes increases the relative risk of 
EAH II and III stages 1.19 and 1.33 times, while 
odds increase 6.08 and 4.75 times (χ2=6.06; p=0.014 
and χ2=5.13; p=0.021, respectively), which is con-
firmed by severity of EAH clinical course. How-
ever, the presence of the above mentioned geno-
types combination makes the likelihood of EAH I 
stage appearance the lowest in the studied patient 
population (OR=0.16; χ2=4.70; p=0.03 and 
OR=0.21; χ2=4.98; p=0.027, respectively). The ab-
sence of mutations in haplotypes (II/GG variant) is 
a protective factor against target-organ damages and 
EAH complications appearance (OR=0.56, p>0.05) 
and 1.44 times (OR=1.80; p>0.05) increases the 
chances for EAH I stage (Table 6).
Risk analysis of pathological changes in the 
geometric structure of the LV in patients with EAH 
based on haplotypes (Table 7) showed a significant 
1.34 and 2.25 times (OR=5.98 and OR=13.5; χ2≤ 
6.01-13.6; p≤0.015-0.001) increase in the proba-
bility of hypertrophic LV options (LV EH and LV 
CH) in ID/TG and DD/TG haplotype carriers, re-
spectively, at the lowest chances for LV NG or CR 
(OR=0.17 and OR=0.07, respectively, χ2≤4.68-
11.6; p≤0.031-0.001). In the EAH patient with II/
GG haplotype the probability of favourable pat-
terns of LV NG and LV CR increases 2.53 times 
(OR=7.87; χ2=5.14; p=0.04), and the risk of LV 
EG and LV CG becomes the lowest in the popula-
tion (OR=0.13; χ2=4.60; p=0.047).
tAble 6.
Haplotypes of ACE and eNOS genes as risk factors for the severity of essential hypertension 
Severity 
of EAH indices
Potential risk factor
ii/tG ii/GG id/tG id/GG dd/tG dd/GG
e
A
h
 ii
 a
nd
 ii
i s
ta
ge
s
ARI / ARR -0.08 0.14 -0.23 -0.11 -0.15 -0.10
RRI / RRR -0.12 0.20 -0.33 -0.15 -0.19 -0.13
RelR 1.12 0.80 1.33 1.15 1.19 1.13
RR 1.30 0.71 3.62 1.48 1.92 1.93
OR 1.54 0.56 6.08 1.87 4.75 2.79
95% СІ RR 0.46-3.67 0.27-1.92 0.97-13.52 0.61-3.55 0.47-18.0 0.34-10.99
95% СІ OR 0.31-7.72 0.09-3.25 1.26-29.3 0.50-7.01 0.51-44.5 0.26-30.27
χ2 <1.0 <1.0 6.06 <1.0 5.13 <1.0
р >0.05 >0.05 0.014 >0.05 0.021 >0.05
e
A
h
 i 
st
ag
e
ARI / ARR 0.08 -0.14 0.23 0.11 0.15 0.11
RRI / RRR 0.27 -0.44 0.78 0.39 0.75 0.59
RelR 0.73 1.44 0.22 0.61 0.25 0.40
RR 0.77 1.40 0.28 0.68 0.34 0.52
OR 0.65 1.8 0.16 0.63 0.21 0.36
95% СІ RR 0.27-2.17 0.52-3.76 0.07-1.03 0.28-1.63 0.06-2.11 0.09-2.96
95% СІ OR 0.13-3.26 0.31-10.52 0.03-0.79 0.14-1.99 0.02-1.97 0.03-3.90
χ2 <1.0 <1.0 4.70 <1.0 4.98 <1.0
р >0.05 >0.05 0.03 >0.05 0.027 >0.05
notes: ARI/ARR – absolute risk increase / absolute risk reduction; RRI/RRR – relative risk increase / relative 
risk reduction; RelR – relative risk; RR – Risk Ratio; OR – Odds Ratio; 95 CІ RR, OR– confidence interval 
of RR, OR; EAH – essential arterial hypertension.
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tAble 7.
Haplotypes of ACE and eNOS genes as risk factors for left ventricular geometry changes in patients 
with essential hypertension
indices
Potential risk factor
ii/tG ii/GG id/tG id/GG dd/tG dd/GG
e
cc
en
tr
ic
 a
nd
 c
on
ce
nt
ri
c 
lV
h
 ARI / ARR -0.09 0.47 -0.24 0.02 -0.50 -0.19
RRI / RRR -0.14 0.68 -0.34 0.03 -1.25 -0.31
RelR 1.14 0.32 1.34 0.97 2.25 1.31
RR 1.31 0.29 3.65 0.95 6.88 1.99
OR 1.56 0.13 5.98 0.91 13.5 2.44
95% СІ RR 0.48-3.69 0.07-1.08 0.92-13.6 0.49-1.84 1.75-27.1 0.63-6.27
95% СІ OR 0.35-7.80 0.02-0.91 1.49-25.1 0.28-2.92 2.75-66.3 0.59-10.2
χ2 <1.0 4.60 6.01 <1.0 13.6 <1.0
р >0.05 0.047 0.015 >0.05 <0.001 >0.05
n
or
m
al
 G
eo
m
et
ry
, C
on
ce
nt
ri
c 
r
em
od
el
in
g 
of
 le
ft 
ve
nt
ri
cl
e 
ARI / ARR 0.09 -0.47 0.24 -0.02 0.50 0.19
RRI / RRR 0.28 -1.53 0.79 -0.07 0.83 0.46
RelR 0.75 2.53 0.23 1.07 0.17 0.54
RR 0.79 3.50 0.29 1.06 0.15 0.50
OR 0.63 7.87 0.17 1.10 0.07 0.41
95% СІ RR 0.27-2.19 0.90-13.24 0.06-1.09 0.54-2.05 0.04-0.57 0.16-1.58
95% СІ OR 0.18-3.30 1.10-56.1 0.05-0.88 0.34-3.53 0.01-0.36 0.10-1.70
χ2 <1.0 5.14 4.68 <1.0 11.6 <1.0
р >0.05 0.04 0.031 >0.05 <0.001 >0.05
notes: ARI/ARR – absolute risk increase / absolute risk reduction; RRI/RRR – relative risk increase / relative 
risk reduction; RelR – relative risk; RR – Risk Ratio; OR – Odds Ratio; 95 CІ RR, OR– confidence interval 
of RR, OR; LVH – left ventricle hypertrophy.
dIScuSSIon
A set of EAH genes-candidates was studied in dif-
ferent ethnic populations, but with contradictory re-
sults. Conducted population, ethnic and racial analysis 
shows that the frequency of unfavorable D allele of 
ACE gene (0.48-0.52) among EAH patients in our sur-
vey corresponds to a majority of Caucasian popula-
tions (0.43-0.56), exceeding the corresponding aver-
aged index in Mongoloid race (0.32-0.40; p<0.05), 
and is slightly lower than in Equatorial race (0.62-0.66; 
p<0.05) [Oeno Hitoshi et al., 1999; Zhang Ying-Min et 
al., 2001; Sekerli E. et al., 2008]. 
The frequency of unfavorable T allele of eNOS 
gene (30.0% – in control, 34.2% – in the experimental 
group) corresponded to that of Caucasian individuals 
(PT=26.5-31.2% – in control, PT=26.5-37.7 – in pa-
tients of the experimental group; p>0.05), being sig-
nificantly higher than in the most of Mongoloid indi-
viduals (P
Tcontrol
=5.8-16.9%, P
Tresearch group
=7.5-21.0%; 
p<0.05) and Equatorial race (PT =8.6%; p<0.05) [Lu-
izon M. et al., 2009; Serrano N. et al., 2010; Li J. et al., 
2011; Ali A. et al., 2012; Metzger I. et al., 2013].
Population analysis of the haplotypes frequency 
in our study shows the presence of unfavourable D 
allele of ACE gene and the T allele of eNOS gene 
(DD/TG, ID/TT haplotypes) in 20.0% cases totally 
(22.5% – in EAH patients, 12.5% – in the controls) 
and that matches to such frequency in Caucasian 
population (20.0-27.0%) and somewhat exceeds 
the figure in Non-caucasian (Asians and African 
Americans) (12.6-15.4%) [Ali A. et al., 2012; Iri-
janto Fredie Nurrohmah et al., 2012; Jun-Ge Han 
et al., 2012; Rahimi Z. et al., 2012]. “Mutant” com-
bination DD/TT was not observed in our patients. 
The relationship between severity of EAH and 
I/D polymorphism of ACE gene is ambiguous: our 
results are consistent with the statements that the 
presence of D-allele of ACE gene in patients with 
previously untreated EAH is a marker of LVH 
[Kuznetsova T. et al., 2000], an independent indi-
cation of target-organ damage and additional car-
diovascular risk factor [Buraczynska M. et al., 
2003], with 2-fold burden of hypertension anam-
nesis, frequent crisis trend, associated with DM2 
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and CHF, higher levels of BP, LVM and concentric 
pattern of LVH [Oeno Hitoshi et al., 1999]. How-
ever, several authors found no relationship of ACE 
gene polymorphism with more severe EAH course; 
these studies were conducted in patients receiving 
long-term antihypertensive therapy [Gomez-An-
gelats E. et al., 2000; Lopez-Contreras J. et al., 
2000; Headley A. et al., 2007]. 
Our findings of the mutant T-allele of eNOS 
gene relationship with the EAH severity and BP 
levels are consistent with the Bogalusa Heart Study 
[Chen W. et al., 2001], while according the fre-
quency of LVH appearance – with data of O.I. Ya-
kovleva and co-workers [Yakovleva O. et al, 2005]. 
However, we found no relation with the intensity 
of LVH and geometric models [Yakovleva O. et al, 
2005; Lapu-Bula R. et al., 2005].
concLuSIon
One third of patients with EAH (35.8%) had a 
mutation in the coding regions of the ACE gene 
(I/D, intron 16, 17q23, dbSNP id: rs4646994) or 
eNOS (894T<G, codon 298 of exon 7, 7q35-36, 
dbSNP id: rs1799983). Every fourth patient (28.3%) 
was the carrier of a pathological DD-genotype of 
ACE gene in a haplotype, whereas the combination 
of homozygous mutations of eNOS gene was ob-
served 4.7 times less frequent (7.5%). A combina-
tion of two abnormal genotypes of both genes (DD/
TT) was not observed. The combined mutation of 
genes ACE (I/D) and eNOS (894T<G) in 8.1% 
(n=13) cases was missing. The most common in the 
observed population group were ID/TG  and ID/GG 
haplotypes (48.1%), both among EAH patients 
(25.8% and 20.0%; p=0.014) and in the control 
group (32.5% and 22.5%; p=0.039), respectively.
Risk-groups of LVH in patients with EAH were 
male DD-genotype carriers and female D-allele carri-
ers of ACE gene, and men with TT genotype of eNOS 
gene. Risk groups of the eccentric or concentric LV 
hypertrophy models frequency were D-allele carriers 
of ACE gene and the T-allele of eNOS gene. The com-
bination of “mutantˮ D and T allele in haplotypes (ID/
TG  and DD/TG  options) 1.19-2.25 times (OR=4.75-
13.5; p≤ 0.021-0.001) increased the relative risk of 
LVH and EAH II and III stages, which was also con-
firmed by the severity of the clinical course of the dis-
ease, with the lowest chance for a normal geometry or 
concentric LV remodeling and the emergence of EAH 
I stage (OR=0.07-0.17; p≤0.031-0.001). 
The absence of mutations in haplotypes (II/GG 
variant) is a protective factor against LVH (OR=0.13; 
p=0.047), emergence of target-organ damage and 
EAH complications (OR=0.56; p> 0.05); further-
more, it increases both the chances for mild EAH I 
stage course (1.44 times; OR=1.80; p>0.05) and the 
number of favourable patterns of LV geometric 
structure (2.53 times; OR=7.87; p=0.04). 
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